Helmut U Klein

List of Publications by Citations

58 papers	13,809 citations	24 h-index	71 g-index
71 ext. papers	16,004 ext. citations	7.7 avg, IF	5.35 L-index

#	Paper	IF	Citations
58	Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *New England Journal of Medicine*, **2002**, 346, 877-83	59.2	5079
57	Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *New England Journal of Medicine*, **1996**, 335, 1933-40	59.2	3200
56	Cardiac-resynchronization therapy for the prevention of heart-failure events. *New England Journal of Medicine*, **2009**, 361, 1329-38	59.2	2105
55	Reduction in inappropriate therapy and mortality through ICD programming. *New England Journal of Medicine*, **2012**, 367, 2275-83	59.2	900
54	Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. *Journal of the American College of Cardiology*, **2008**, 51, 1357-65	15.1	612
53	Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. *European Heart Journal*, **2011**, 32, 847-55	9.5	354
52	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. *European Heart Journal*, **2015**, 36, 425-33	9.5	208
51	Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. *PACE - Pacing and Clinical Electrophysiology*, **2004**, 27, 4-9	1.6	160
50	Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). *Circulation*, **2015**, 132, 1613-9	16.7	148
49	Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). *PACE - Pacing and Clinical Electrophysiology*, **2010**, 33, 353-67	1.6	101
48	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. *European Journal of Heart Failure*, **2014**, 16, 1331-6	12.3	93
47	Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 785-92	6.4	85
46	Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. *European Heart Journal*, **2013**, 34, 2230-42	9.5	84
45	Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. *American Journal of Cardiology*, **1998**, 81, 1253-6	3	68
44	Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 2016-22	1.6	55
43	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. *International Journal of Cardiology*, **2017**, 244, 229-234	3.2	54
42	Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. *European Journal of Heart Failure*, **2014**, 16, 692-9	12.3	42

41	The wearable cardioverter-defibrillator: current technology and evolving indications. *Europace*, **2017**, 19, 335-345	3.9	41
40	Vagus nerve stimulation: A new approach to reduce heart failure. *Cardiology Journal*, **2010**, 17, 638-44	1.4	41
39	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. *Clinical Research in Cardiology*, **2016**, 105, 944-952	6.1	32
38	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. *Europace*, **2015**, 17, 1259-66	3.9	32
37	Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. *American Journal of Cardiology*, **2011**, 108, 1632-8	3	28
36	Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. *American Heart Journal*, **2017**, 189, 158-166	4.9	27
35	Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. *Journal of the American Heart Association*, **2015**, 4,	6	25
34	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. *ESC Heart Failure*, **2020**, 7, 75-83	3.7	23
33	The effect of ICD programming on inappropriate and appropriate ICD Therapies in ischemic and nonischemic cardiomyopathy: the MADIT-RIT trial. *Journal of Cardiovascular Electrophysiology*, **2015** , 26, 424-433	2.7	21
32	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. *Heart*, **2016** , 102, 1742-1749	5.1	21
31	Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. *Circulation: Heart Failure*, **2019**, 12, e005879	7.6	21
30	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. *European Heart Journal*, **2021**, 42, 1676-1684	9.5	16
29	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. *Circulation: Heart Failure*, **2015**, 8, 725-32	7.6	15
28	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. *Europace*, **2015**, 17, 1085-91	3.9	14
27	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. *Europace*, **2017**, 19, 1549-1555	3.9	14
26	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. *JACC: Clinical Electrophysiology*, **2018**, 4, 1410-1420	4.6	11
25	One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). *PACE - Pacing and Clinical Electrophysiology*, **2018**, 41, 1307-1313	1.6	9
24	Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. *Europace*, **2018**, 20, f225-f232	3.9	9

23	A metric for evaluating the cardiac response to resynchronization therapy. *American Journal of Cardiology*, **2014**, 113, 1371-7	3	9
22	Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. *Clinical Research in Cardiology*, **2021**, 110, 102-113	6.1	6
21	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. *Heart Rhythm*, **2018**, 15, 1379-1386	6.7	6
20	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. *Journal of Cardiac Failure*, **2016**, 22, 143-9	3.3	5
19	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. *Europace*, **2019**, 21, 1843-1850	3.9	5
18	Safety of the Wearable Cardioverter Defibrillator (WCD) in Patients with Implanted Pacemakers. *PACE - Pacing and Clinical Electrophysiology*, **2017**, 40, 271-277	1.6	4
17	Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. *Heart Rhythm*, **2014**, 11, 1001-7	6.7	4
16	Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy. *PACE - Pacing and Clinical Electrophysiology*, **2017**, 40, 9-16	1.6	4
15	Comparison of Long-Term Survival Benefits With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Versus Without Diabetes Mellitus (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy [MADIT-CRT]). *American Journal of Cardiology*, **2018**, 121, 1567-1574	3	3
14	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. *Journal of Interventional Cardiac Electrophysiology*, **2018**, 52, 185-194	2.4	3
13	Implantable defibrillators: 30 years of history **2010**, 11, 48S-52S		3
12	The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time. *American Heart Journal*, **2017**, 186, 111-117	4.9	2
11	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. *Annals of Noninvasive Electrocardiology*, **2017**, 22,	1.5	2
10	Response to letter regarding, "PR interval identifies clinical response in patients with non-left bundle branch block: a multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy sub-study" by Kutyifa et al. *Circulation: Arrhythmia and Electrophysiology*, **2014**, 7, 1280	6.4	1
9	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.. *Frontiers in Physiology*, **2022**, 13, 857538	4.6	1
8	Michel Mirowski and the beginning of a new era of fighting sudden arrhythmic death. *Herzschrittmachertherapie Und Elektrophysiologie*, **2015**, 26, 61-9	0.8	0
7	Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients. *Current Treatment Options in Cardiovascular Medicine*, **2010**, 12, 431-42	2.1	0
6	Arthur Jay Moss MD PhD: The cardiology world has again lost one of its most respected and worldwide-honoured scholars and experienced clinician. Born 21 June 1931, Professor of Medicine and Cardiology at Rochester University Medical Center, Rochester, NY, Arthur passed away on 14 February 2018 at the age of 86. *European Heart Journal*, **2018**, 39, 1872-1874	9.5	

5	Preventive cardiac resynchronisation therapy. *Heart*, **2012**, 98, 508-15	5.1
4	The Wearable Cardioverter Defibrillator-Bridge to the Implantable Defibrillator. *Cardiac Electrophysiology Clinics*, **2009**, 1, 129-146	1.4
3	Considering the Need to Expand the Indications for Wearable Defibrillator Therapy. *Journal of Innovations in Cardiac Rhythm Management*, **2019**, 10, 3751-3760	1.1
2	Letter to the Editor- Prognostic implication of baseline PR interval in patients undergoing cardiac resynchronization therapy. *Heart Rhythm*, **2016**, 13, 1573	6.7
1	No Utility of the Wearable Cardioverter-Defibrillator in Patients With Nonischemic Cardiomyopathy?. *Journal of the American College of Cardiology*, **2016**, 67, 2807	15.1